All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 26, 2023
Home » Blogs » BioWorld Perspectives » Life and death and #BIO2017

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Life and death and #BIO2017

June 26, 2017
By Marie Powers
No Comments

iStock-521624342I missed BIO this year – the first time in 40 years as a journalist that I canceled attendance at a major conference due to a death in the family. About 12 hours before I was due to board a plane to San Diego, my brother in-law, Kevin, had a massive heart attack and died at the age of 64.

In life, Kevin was what health care professionals likely would describe as a “challenging” patient. Like his father, he was subject to familial hypercholesterolemia. Unlike his dad, who had a proverbial “warning shot” in his 40s and then embraced a rigorous routine of diet, medication and exercise before succumbing to a fatal heart attack at 78, Kevin didn’t take especially good care of himself. He was overweight. He shirked visits to doctors and generally ignored their advice. At the urging of family members, he had a stress test several years ago that revealed several partial blockages and only reluctantly agreed to medical intervention.

But Kevin also faced a number of challenges in life that conspired against him. As he approached his 60s, he juggled minimum wage and temporary work, was intermittently uninsured and, for a time, was a whisper from homelessness. In short, Kevin’s life mirrored those of millions of adults in the U.S. His life was messy and dysfunctional – characteristics that are true, to some extent, of each and every one of us.

I don’t know if Kevin was prescribed a PCSK9 – a class of drugs that might have extended his life. Even if one was prescribed, he likely couldn’t afford the medication and certainly wouldn’t have jumped through the hoops that are required of patients to seek financial assistance.

So in the days before Kevin’s funeral, watching from afar as the news flowed from BIO, I was struck by a tremendous sense of irony. Although BIO has touted its efforts, especially in recent years, to put patients first, the scenes that played out on social media sent a decidedly mixed message. Despite this era of “value-based drug pricing” – much ballyhooed at #BIO2017 – scenes of sailboats, splashy logos, parties in Petco Park and drug company pavilions received as much play as educational sessions and hard data. It behooves the industry to remember that patients in need of access to life-changing medications also were watching the extravagance that was flaunted at BIO.

Of course, payers and pharmacy benefit managers (PBMs) also wield very big sticks in decisions about drug pricing and access, and each opponent in this ongoing contest has been adept at pointing fingers at the others – often while spouting the same lip service to the patient community. Reading statements from a BIO panel on drug pricing that included the usual suspects – some of whom I’ve interviewed on the same topic – was akin to watching a rerun of an old TV show with a predictable plot and the same tired dialogue.

Watching the drug pricing drama play out, I’m left with troubling questions. Do biopharmas actually seek out patients who don’t look out for themselves? Patients who don’t fit into a neat niche under the umbrella of a powerful advocacy organization? Who aren’t telegenic or have a compelling backstory? Is a biopharma’s due diligence to the patient community fulfilled by developing glossy print ads and clever television campaigns rather than working painstakingly with providers to reach underserved populations? Despite their public rhetoric, are payers, PBMs and biopharmas content to grab the low-hanging fruit instead of reaching out to individuals who need more hand-holding, more understanding, more compassion?

As a journalist, it’s my job to report what people say and what they do without making judgments. That’s the reader’s job. But reflecting about the life and death of a loved one during a week when the BIO world was letting its hair down in San Diego was another matter altogether. And it was painfully obvious that – even when on script – the industry’s public actions ultimately speak louder than its words.

 

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 24, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 24, 2022.
  • Kirill Pevzner and Eran Seger - Protai

    AI drug discovery startup Protai raises $12M in seed funding

    BioWorld
    Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20...
  • Pfizer-Seagen logos on puzzle pieces

    Pfizer to buy Seagen for $43B

    BioWorld
    Pfizer Inc.’s appetite for acquisitions shows no signs of abating as it announced this morning its plan to acquire biotech Seagen Inc. for a whopping $43 billion...
  • In war against T1D onset, Tzield-bearer Provention’s comrade Sanofi plans $2.9B takeover

    BioWorld
    Shares of Provention Bio Inc. (NASDAQ:PRVB) closed March 13 at $24.10, up $17.40, or 259%, after Wall Street learned that collaborator Sanofi SA intends to...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing